Results 31 to 40 of about 1,927 (159)

Phenotypic susceptibility of HIV-2 to raltegravir [PDF]

AIDS, 2011
Raltegravir is the first integrase strand transfer inhibitor approved for treating HIV-1 infection. Although emerging data suggest that raltegravir may also be useful for HIV-2 treatment, studies addressing the in-vitro susceptibility of HIV-2 to raltegravir are scarce, and the genetic pathways leading to raltegravir resistance in HIV-2 have not been ...
Nancy B. Kiviat, Papa Salif Sow, Robert A. Smith, Dana N. Raugi, Stephen E. Hawes, Geoffrey S. Gottlieb, James I. Mullins   +6 more
openaire   +3 more sources

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence

Frontiers in Microbiology, 2019
The human immunodeficiency virus type 1 (HIV-1) has several proteins of therapeutic importance, many of which are currently used as drug targets in antiretroviral therapy. Among these proteins is the integrase, which is responsible for the integration of
Lucas de Almeida Machado, Marcelo Ferreira da Costa Gomes, Ana Carolina Ramos Guimarães   +2 more
doaj   +1 more source

Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration

Clinical Pharmacology &Therapeutics, EarlyView.
Atazanavir has been reported to increase total serum bilirubin level up to ninefold. It is widely believed that the observed total bilirubin elevation is primarily due to UGT1A1 inhibition. However, UGT enzymes are well‐known as a low‐affinity and high‐capacity system, and the observed drug–drug interaction mediated by UGTs is usually less than twofold.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

The Journal of Clinical Pharmacology, EarlyView.
Abstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Olivier Schueller, Lauren Lohmer, Felix Beck, Jeegar Patel, Jasminder Sahi   +4 more
wiley   +1 more source

Undetectable proviral DNA and viral RNA levels after raltegravir administration in two cats with natural feline leukemia virus infection

Brazilian Journal of Veterinary Medicine, 2022
Feline leukemia virus (FeLV) infection was discovered over 50 years ago; however, the serious clinical changes associated with FeLV infection still have great importance in the diagnosis, prevention, and clinical management of symptomatic patients ...
Carla Regina Gomes Rodrigues Santos, Isabela Torres Ferreira, Renata Beranger, Julia Possebon Santi, Mariana Palha de Brito Jardim, Heloisa Justen Moreira de Souza   +5 more
doaj   +1 more source

Using the Simcyp R Package for PBPK Simulation Workflows With the Simcyp Simulator

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) modeling aims to understand how a drug is absorbed, distributed, metabolized, excreted, and acts in a human or animal body. The Simcyp Simulator is a well‐known commercial PBPK/PD simulation software offering many options.
Anthonia M. Onasanwo, Naresh Mittapelly, Laura Shireman, Barry Vinden, Kevin McNally, James Craig, Frederic Y. Bois   +6 more
wiley   +1 more source

Evolution of raltegravir resistance during therapy [PDF]

Journal of Antimicrobial Chemotherapy, 2009
We investigated the prevalence of raltegravir resistance-associated mutations at baseline and their evolution during raltegravir therapy in patients infected with different HIV-1 subtypes.At pre-treatment screening, the integrase gene from plasma samples from patients infected with subtype B and non-B viruses was analysed.
Gerd Fätkenheuer, Martin Däumer, Saleta Sierra, Eugen Schülter, Rolf Kaiser, Nadine Sichtig, Andre Altmann, Stefan Reuter, Ulf Dittmer, Herbert Pfister, Stefan Esser   +10 more
openaire   +3 more sources

HIV INTEGRASE INHIBITORS: THE BASIS OF EFFECTIVE AND SAFE ANTIRETROVIRAL THERAPY

Медицинский совет, 2017
The article examines the efficacy and safety of HIV integrase inhibitors (raltegravir, dolutegravir) in antiretroviral therapy (ART) regimens in various groups of HIV-infected patients: patients with high HIV RNA blood levels, patients with low CD4 ...
V. I. SHAKHGILDYAN
doaj   +1 more source

Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use

HIV Medicine, EarlyView.
Abstract Introduction Integrase strand transfer inhibitors (INSTIs) are the mainstay of treatment in adults and children living with HIV. Weight gain has been associated with INSTI use in adults; however, less data exist on its effects on younger patients.
Kathleen J. Pincus, Nabila Faridi, Patrick Amadeus Ryscavage, Hyunuk Seung, Kristine A. Parbuoni, Matthew Grant, Neha Sheth Pandit   +6 more
wiley   +1 more source

DRESS syndrome associated with raltegravir

Dermatology Online Journal, 2011
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome or drug-induced hypersensitivity is a potentially life-threatening drug hypersensitivity syndrome most commonly associated with anticonvulsants, allopurinol, long-acting sulfonamides, dapsone, and minocycline.
Zhang, Kevin S, Modi, Gunjan M, Hsu, Sylvia   +2 more
openaire   +3 more sources